Allergan, Inamed unite
This article was originally published in The Gray Sheet
Executive Summary
After a series of delays, Allergan finally nabs more than 90% of outstanding Inamed shares to complete its acquisition of the aesthetics firm. On March 23, Allergan announced that thanks to one final extension, Inamed shareholders had tendered nearly 94% of outstanding stock by the March 17 deadline, allowing the $3.2 bil. deal to proceed under Delaware's short-form merger statute. Though nearly all Inamed shareholders elected to receive Allergan stock, under the terms of the deal Allergan will instead give the shareholders 0.46 shares of Allergan and $37.71 for each share of Inamed...
You may also be interested in...
Allergan Details Revenue Expectations From Newly Acquired Inamed
Allergan expects its recently completed acquisition of Inamed to add $355 mil. to $395 mil. in sales revenue this year
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.